These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33789472)

  • 1. Limited progression of subclinical Dupuytren's disease.
    van den Berge BA; Werker PMN; Broekstra DC
    Bone Joint J; 2021 Apr; 103-B(4):704-710. PubMed ID: 33789472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence.
    Hindocha S; Stanley JK; Watson S; Bayat A
    J Hand Surg Am; 2006 Dec; 31(10):1626-34. PubMed ID: 17145383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between echogenicity and progression of Dupuytren's disease (DD): Birth of an imaging biomarker?
    van Straalen RJM; de Boer MR; Molenkamp S; Maas M; Werker PMN; Broekstra DC
    J Plast Reconstr Aesthet Surg; 2023 Nov; 86():222-230. PubMed ID: 37782995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupuytren's disease in type 1 diabetic patients: a five-year prospective study.
    Arkkila PE; Kantola IM; Viikari JS; Rönnemaa T; Vähätalo MA
    Clin Exp Rheumatol; 1996; 14(1):59-65. PubMed ID: 8697659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of genetic susceptibility in Dupuytren's disease.
    Becker K; Tinschert S; Lienert A; Bleuler PE; Staub F; Meinel A; Rößler J; Wach W; Hoffmann R; Kühnel F; Damert HG; Nick HE; Spicher R; Lenze W; Langer M; Nürnberg P; Hennies HC
    Clin Genet; 2015 May; 87(5):483-7. PubMed ID: 24749973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: Dupuytren's disease in Asia and the migration theory of Dupuytren's disease.
    Slattery D
    ANZ J Surg; 2010; 80(7-8):495-9. PubMed ID: 20795961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic factors and the risk of Dupuytren's disease: data from 30,000 individuals followed for over 20 years.
    Rydberg M; Zimmerman M; Löfgren JP; Gottsäter A; Nilsson PM; Melander O; Dahlin LB
    Sci Rep; 2021 Jul; 11(1):14669. PubMed ID: 34282190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of Dupuytren's Disease in Japanese General Population.
    Sasaki N; Uesato R; Yamauchi T; Ishibashi Y; Nakaji S
    J Hand Surg Asian Pac Vol; 2021 Jun; 26(2):229-234. PubMed ID: 33928865
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiological study for personal risk factors and quality of life related to Dupuytren's disease in a mountain village of Japan.
    Tajika T; Kobayashi T; Kaneko T; Tsunoda D; Tsunoda K; Sutou T; Yamamoto A; Takagishi K
    J Orthop Sci; 2014 Jan; 19(1):64-70. PubMed ID: 24129389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What do we know about managing Dupuytren's disease cost-effectively?
    Dritsaki M; Rivero-Arias O; Gray A; Ball C; Nanchahal J
    BMC Musculoskelet Disord; 2018 Jan; 19(1):34. PubMed ID: 29370792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Radiotherapy in the early stage of Dupuytren's disease. The indications, technic and long-term results].
    Keilholz L; Seegenschmiedt MH; Born AD; Sauer R
    Strahlenther Onkol; 1997 Jan; 173(1):27-35. PubMed ID: 9082583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The heritability of Dupuytren's disease: familial aggregation and its clinical significance.
    Hindocha S; John S; Stanley JK; Watson SJ; Bayat A
    J Hand Surg Am; 2006 Feb; 31(2):204-10. PubMed ID: 16473680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Recurrent Surgery in Dupuytren's Disease: Comparison with Initial Treatment.
    Mendelaar NHA; Poelstra R; van Nieuwenhoven CA; Slijper HP; Feitz R; Hovius SER; Selles RW
    Plast Reconstr Surg; 2019 Nov; 144(5):828e-835e. PubMed ID: 31397794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Weighted Genetic Risk Score Predicts Surgical Recurrence Independent of High-Risk Clinical Features in Dupuytren's Disease.
    Riesmeijer SA; Manley OWG; Ng M; Nolte IM; Broekstra DC; Werker PMN; Furniss D
    Plast Reconstr Surg; 2019 Feb; 143(2):512-518. PubMed ID: 30688894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical presentation and types of Dupuytren's disease.
    Rayan GM
    Hand Clin; 1999 Feb; 15(1):87-96, vii. PubMed ID: 10050245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective review of the management of Dupuytren's nodules.
    Reilly RM; Stern PJ; Goldfarb CA
    J Hand Surg Am; 2005 Sep; 30(5):1014-8. PubMed ID: 16182060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of Dupuytren's contracture: A consensus-based definition.
    Kan HJ; Verrijp FW; Hovius SER; van Nieuwenhoven CA; ; Selles RW
    PLoS One; 2017; 12(5):e0164849. PubMed ID: 28505187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.
    Simón-Pérez C; Alía-Ortega J; García-Medrano B; Rodríguez-Mateos JI; Brotat-Rodríguez M; Aguado-Hernandez H; Martín-Ferrero MA
    Int Orthop; 2018 Apr; 42(4):859-866. PubMed ID: 29170879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGF-R) in Dupuytren's disease.
    Augoff K; Taboła R; Kula J; Gosk J; Rutowski R
    J Hand Surg Br; 2005 Dec; 30(6):570-3. PubMed ID: 16055243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupuytren's disease is a work-related disorder: results of a population-based cohort study.
    van den Berge BA; Wiberg A; Werker PMN; Broekstra DC; Furniss D
    Occup Environ Med; 2023 Mar; 80(3):137-145. PubMed ID: 36635095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.